Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Journal of clinical oncology, 2021-09, Vol.39 (27), p.2991-3001 [Peer Reviewed Journal]2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.20.03555 ;PMID: 34292792
Full text available